Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Novartis patent term dabrafenib?
Drugpatentwatch evista historical sales market context?
Diltiazem drug class?
Can i take anti histamine with statin?
What excipients are combined with ruxolitinib in apotex's medication?

Ultomiris patent expiration date?

See the DrugPatentWatch profile for Ultomiris

Ultomiris: A New Era for Patients, But at What Cost to Payers?

When Does the Ultomiris Patent Expire?

The Ultomiris patent is set to expire in 2026, according to the patent information available on DrugPatentWatch.com [1].

What Happens After Expiration? Will Biosimilars Enter the Market?

After the patent expires, biosimilar manufacturers will be able to develop and launch their versions of Ultomiris. This could lead to increased competition and potentially lower prices for patients. [2]

How Will the Expiration Affect Patients with PNH or aHUS?

The expiration of the patent may impact the affordability of Ultomiris for patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). This may affect their access to the treatment, potentially forcing them to rely on alternative therapies.

Why Are Companies Challenging the Patent?

Roche, the manufacturer of Ultomiris, continues to face patent challenges from rival companies. This could complicate the approval process for biosimilars and delay their release to the market [3].

Will Exclusivity for Ultomiris Last Until 2026?

The patent expiration date is set for 2026, but exclusivity may end earlier due to regulatory challenges or court decisions. As such, biosimilar manufacturers may see opportunities to enter the market before the patent fully expires.

References

[1] DrugPatentWatch.com - Ultomiris (ravulizumab) Patent Expiration Date

[2] MarketWatch - Biosimilars: The future of the biotechnology industry, 2022

[3] Reuters - Roche faces patent challenge from AbbVie, 2024

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided AI claims focus on patent expiration, biosimilar entry, market competition, and affordability. The FDA label excerpts supplied are specific to serious meningococcal infection risk (warnings/precautions), contraindications, vaccination/prophylaxis, REMS requirements, and limited adverse reaction information, and do not address patent timelines, exclusivity, biosimilar launch conditions, or pricing/affordability. As a result, alignment to prescribing information cannot be determined from the information provided.

Alignment Scorecard

Category	Status	Notes
Indication	Unable to Assess	AI claims are about patents/market access, not approved indications in the provided label excerpt.
Patient Population	Unable to Assess	AI mentions PNH/aHUS only in the context of affordability; the provided label excerpts do not discuss these populations.
Dosage & Administration	Not Addressed	The provided label excerpt includes vaccination/prophylaxis timing, but none of the AI claims address dosing/administration.
Contraindications	Not Applicable	AI claims do not address contraindications.
Warnings & Precautions	Not Applicable	AI claims are not about the labeled meningococcal infection warning and precautions.
Drug Interactions	Not Applicable	Not addressed in the provided AI claims or label excerpts.
Adverse Reactions	Not Applicable	AI claims do not address adverse reactions.
Monitoring	Not Applicable	Monitoring requirements for meningococcal infection are in the label excerpt, but AI claims do not reference monitoring.
Administration Instructions	Not Addressed	Label instructions in the excerpt (vaccination/prophylaxis/REMS) are not reflected in the AI claims.
Limitations of Use	Not Addressed	Not addressed in AI claims or provided label excerpt sections.
Special Populations	Not Addressed	Only PNH/aHUS are mentioned by AI without label support in the provided excerpts.

Key Findings

All AI claims are outside the scope of the prescribing information excerpts provided (serious meningococcal infection risk, contraindication, vaccination/prophylaxis, and REMS).
No evidence is provided in the supplied label excerpts to support assertions about patent expiration (2026), biosimilar launch timing, exclusivity, competition, pricing, or required reliance on alternative therapies.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Ultomiris patent is set to expire in 2026.	Cannot Determine	Provided FDA label excerpts do not discuss patent expiration dates or regulatory exclusivity periods.	Informational
After the patent expires, biosimilar manufacturers will be able to develop and launch versions of Ultomiris.	Cannot Determine	Provided label excerpts do not address biosimilar development/launch conditions, patent linkage, or exclusivity mechanisms.	Moderate
After the patent expires, increased competition for Ultomiris could potentially lower prices for patients.	Cannot Determine	No label excerpt provided addresses pricing, affordability, or market competition effects.	Moderate
The expiration of the patent may impact the affordability of Ultomiris for patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).	Cannot Determine	Provided label excerpts do not discuss PNH/aHUS populations or affordability impacts tied to patent expiration.	Moderate
If affordability/access is affected by patent expiration, patients with PNH or aHUS may be forced to rely on alternative therapies.	Cannot Determine	Label excerpts do not discuss access outcomes or recommendations/constraints to use alternative therapies.	High
Roche continues to face patent challenges from rival companies regarding Ultomiris.	Cannot Determine	Prescribing information excerpts do not include litigation or patent challenge status.	Informational
Patent challenges could complicate the approval process for biosimilars and delay their release to the market.	Cannot Determine	Provided label excerpts do not describe the biosimilar approval timeline or effects of patent challenges.	Moderate
Exclusivity for Ultomiris may end earlier than the 2026 patent expiration date due to regulatory challenges or court decisions.	Cannot Determine	No label excerpt provides details about exclusivity end dates, court decisions, or regulatory challenges.	Moderate
Biosimilar manufacturers may be able to enter the market before the patent fully expires.	Cannot Determine	Provided label excerpts do not address market entry conditions prior to patent/exclusivity expiration.	Moderate

Important Omissions

No alignment assessment is possible for the patent/biosimilar/price/access claims because the provided FDA label excerpts do not cover these topics.
The label excerpt provided is focused on meningococcal infection risk (Warnings/Precautions), contraindication for unresolved serious Neisseria meningitidis infection, and REMS/vaccination/prophylaxis requirements; none of the AI claims address these labeled safety elements.

Unsupported / Hallucinated Content

No specific patent date (2026), exclusivity timing, litigation status, biosimilar approval delays, or affordability/access consequences are supported by the supplied prescribing-information excerpts.

Potential Patient Safety Concerns

The claims may create expectations about availability, access, or need to use alternative therapies. The provided prescribing-information excerpts do not substantiate these market/access statements, so they should not be used as a basis for patient management decisions.

Overall Assessment

Based on the FDA label excerpts provided (serious meningococcal infection risk, contraindication, vaccination/prophylaxis, and REMS counseling), the AI claims about patent expiration, biosimilar entry timing, exclusivity ending earlier, pricing effects, and potential reliance on alternative therapies cannot be verified for alignment. The AI response does not reference or reflect the labeled prescribing information content included in the excerpts.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

Ultomiris patent is set to expire in 2026

Core Claims

Ultomiris patent is set to expire in 2026
After expiration, biosimilar manufacturers can develop and launch versions of Ultomiris
Patent expiration may impact affordability and access for PNH or aHUS patients

Differentiators

Biosimilar competition could potentially lower prices for patients
Roche faces patent challenges that could delay biosimilar release

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
Roche	35%	50	#4	No
AbbVie	35%	50	#5	No